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Introduction {#sec1}
============

Articular cartilage is essential for mechanical load-bearing and joint-surface lubrication. Despite its lifelong requirement, human cartilage possesses poor self-renewal capacity against trauma and degeneration ([@bib20]), and its function loss results in joint pain and reduced quality of life. Cartilage defects are really common; a recent study has cited a national knee cartilage surgery incidence of 56 per 100,000 person-years ([@bib11]). If left untreated, cartilage focal defects can lead to osteoarthritis and even permanent damage ([@bib18]). In recent decades, advances in regenerative medicine have brought improvements in the treatment of early cartilage defects, using autologous chondrocyte implantation, a minimally invasive technique showing promising results for cartilage healing ([@bib38]). This approach has limitations: scar-like tissue (fibrocartilage) rather than intact repair tissue (hyaline cartilage) was produced. Indeed, degeneration and fibrosis at articular cartilage surfaces remains a serious challenge in clinical practice ([@bib8], [@bib48]). The lack of functional chondrocytes demands a development of alternative cell sources for articular regeneration.

It has been suggested that specific cell types may be generated by direct conversion of one cell type to another, avoiding passing through a pluripotent stage. This process, termed trans-differentiation or direct reprogramming ([@bib25]), was initially achieved by forced expression of defined transcriptional factors ([@bib16], [@bib35]). More recently, small-molecule reprogramming agents have become popular given their non-tumorigenic, cell permeable, and non-immunogenic advantages ([@bib19]). Virus-free chemical conversion of fibroblasts into neural progenitors ([@bib50], [@bib51]) and cardiomyocyte lineages ([@bib50], [@bib51]) has highlighted its potential applications in regenerative medicine. Yet, despite the successes in cardiomyocytes and neural lineage reprogramming, virus-free induction of fibroblasts into articular chondrocytes has not been reported. Moreover, the induction of chemical reprogramming is a meticulous and complicated process, critical for both the final cell yield and tissue repair. Because of the heterogeneity of cell population being reprogrammed, a sophisticated dissection of dynamical processes at single-cell resolution is necessary, and may provide insights for future applications.

In this study, we have developed a cocktail of five small-molecule compounds, VCRTc (valproic acid, CHIR98014, Repsox, TTNPB, and celecoxib), which converts fibroblasts into articular chondrocytes. We used high-throughput single-cell transcriptomics to systematically analyze the cellular phenotypic changes that occurred in the cell fate transition from fibroblast to the intermediate chondrogenic progenitor state during early reprogramming. We also verified the biological function of the chemical-induced chondrocytes by implanting them into defective articular cartilage to promote its mechanical recovery. Thus, in this proof-of-concept study, we have developed, and characterized, a chemical method to derive functional chondrocytes from fibroblasts, laying the foundation for the application of chemical-induced cell fate reprogramming in cartilage regenerative therapies.

Results {#sec2}
=======

Efficient Fibroblast-to-Chondrocyte Conversion Using a Chemical Cocktail {#sec2.1}
------------------------------------------------------------------------

To develop a chemical cocktail that enables fibroblast-to-chondrocyte conversion, we used a two-stage model for the induction of mouse embryonic fibroblasts (MEFs) based on published results showing that direct reprogramming is a stepwise process ([Figure 1](#fig1){ref-type="fig"}A) ([@bib5]).Figure 1Efficient Fibroblast-to-Chondrocyte Conversion Using a Chemical Cocktail(A) Schematic diagram of screening strategy for fibroblast-to-chondrocyte reprogramming. MEFs, mouse embryonic fibroblasts.(B) Representative images of negative and positive controls for Safranin O-fast green staining. Negative/positive controls: MEFs and mouse mesenchymal stem cell line (C3H/10T1/2) cultured in chondrogenic differentiation medium for 14 days. Scare bars, 200 μm.(C) Representative images of chemical-induced chondrocyte (ci-chon) clusters, stained by Safranin O-fast green, and immunostained by SOX9 and collagen type II (COL2) antibodies. Scale bars, 50 μm.(D) Col2-pd2EGFP fluorescence observation during chemical reprogramming. Scale bar, 50 μm.(E) Quantification of cell number in Safranin O^+^ clusters induced by candidate cocktails in combinatory screening. V, valproic acid (VPA); C, CHIR98014; R, Repsox; T, TTNPB; c, celecoxib; O, olanzapine; D, dopamine HCl. Independent experiments, n = 3.(F) Percentage of Col2-pd2EGFP^+^ cells induced by candidate cocktails. Independent experiments, n = 3.(G) Representative images of Safranin O staining and Col2-pd2EGFP fluorescence in ci-chons derived from VCR- and VCRTc-treated MEFs. Scale bars, 50 μm.(H) Schematic diagram of the two-step strategy with the optimal combination VCRTc.Data are means ± SEM, n ≥ 3. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. See also in [Figure S1](#mmc1){ref-type="supplementary-material"}.

To confirm that the obtained primary MEFs were free of chondrogenic subpopulations, we removed all tissues from head, limbs, visceral tissues, gonads, vertebral column, rib, and sternum during cell isolation. Direct chondrogenesis of MEFs led to fibrous tissues, and no cartilage matrix, which was stained in green by Safranin O-fast green ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Immunostaining demonstrated that the MEFs treated by chondrogenesis medium expressed the fibroblast marker collagen type I (COL1), and not the chondrocyte marker collagen type II (COL2) ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1C). Using Col2-pd2EGFP reporter mice ([@bib45]), a strain harboring a *Col2-pd2EGFP* transgene driven by *Col2a1* promotor/enhancer, we also demonstrated the poor chondrogenesis ability of untreated MEFs ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C).

During stage 1 of the induction, expanded MEFs were treated with chemical cocktails under 5% O~2~ for 6 days. Basic chemicals in stage 1 contained valproic acid (V, histone deacetylase inhibitor), CHIR98014 (C, GSK-3 kinases inhibitor), and Repsox (R, transforming growth factor β \[TGF-β\] inhibitor), as they have been used to facilitate the direct reprogramming of other lineages ([@bib5], [@bib17]).

Stage 2 involved culturing the cocktail-treated cells in chondrogenic differentiation medium for an additional 14 days (days 6--20). At the end of the induction, we calculated the cell number in Safranin O^+^ clusters to quantify the fibroblast-to-chondrocyte conversion ([Figure 1](#fig1){ref-type="fig"}B), as Safranin O-fast green staining was used for chondrocyte glycosaminoglycan recognition ([@bib34]). Immunostaining for chondrocyte markers SOX9 and COL2 was conducted to characterize their chondrocyte identity ([Figure 1](#fig1){ref-type="fig"}C). Using Col2-pd2EGFP reporter mice, we also demonstrated the real-time expression of chondrocyte marker Col2 ([Figure 1](#fig1){ref-type="fig"}D). The cellular morphology of MEFs changed into polygonal after chemical reprogramming ([Figure S1](#mmc1){ref-type="supplementary-material"}D).

Elimination of individual components of VCR, and extension of induction time during stage 1 reduced the formation of Safranin O^+^ cells ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F). TGF-β3 was identified as an essential component for chondrogenic medium in stage 2 ([Figures S1](#mmc1){ref-type="supplementary-material"}H and S1I). Thus, these results validated the establishment of the basic model. We used VCR treatment followed by culturing in chondrogenic medium as a basis for further optimizing our induction system.

To identify additional chemical compounds capable of boosting the fibroblast-to-chondrocyte conversion, we screened a library of 48 small molecules known to facilitate reprogramming or regulate chondrogenesis ([Table S1](#mmc1){ref-type="supplementary-material"}). In primary screening, each compound was added either at stage 1 or 2 ([Figure 1](#fig1){ref-type="fig"}A). We identified five compounds, treatment with which, together with the VCR cocktail during stage 1, potentially increased the Safranin O^+^ efficiency ([Figure S1](#mmc1){ref-type="supplementary-material"}J). These were kartogenin (Kgn, K), olanzapine (O), dopamine HCl (D), celecoxib (c), and TTNPB (T) ([Table S2](#mmc1){ref-type="supplementary-material"}). We tested 30 different combinations of these five candidates and found that the combination of TTNPB (a retinoic acid receptor agonist) and celecoxib (a cyclooxygenase \[COX\] 2 inhibitor) ([Figure S1](#mmc1){ref-type="supplementary-material"}L) together with the VCR (VCRTc) led to one of the best outcomes ([Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}K). We further validated the function of the candidate combinations by reprogramming Col2-pd2EGFP MEFs ([Figures 1](#fig1){ref-type="fig"}F and 1G). When compared with other groups, cocktail VCRTc resulted in the greatest conversion efficiency, which increased the initial efficiency (VCR group) by ∼4-fold ([Figures 1](#fig1){ref-type="fig"}E and 1F). Altogether, we have established a chemical reprogramming system to convert MEFs into chondrocytes using chemical cocktail VCRTc ([Figure 1](#fig1){ref-type="fig"}H).

Chemical-Induced Chondrocytes Form Scaffold-free Cartilage Organoids {#sec2.2}
--------------------------------------------------------------------

The micro-mechanical environment provided by 3D cultures has been reported to be essential for chondrogenesis ([@bib3]). We, therefore, applied bionic 3D culture to the generation of chemical-induced chondrocytes (ci-chons). Although VCRTc produced the most efficient lineage conversion among other groups, the *Col2*^+^ efficiency in monolayer culture was still low (∼1%) ([Figure 1](#fig1){ref-type="fig"}F). Thus we adopted a high-density micromass culture to promote chondrogenesis during stage 2, using Col2-pd2EGFP MEFs. VCRTc-treated MEFs formed small aggregations spontaneously after micromass attachment ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). These aggregations continued to increase in size and express *Col2* ([Figure S2](#mmc1){ref-type="supplementary-material"}A), and the immunostaining images showed they were SOX9^+^ and COL2^+^ ([Figure S2](#mmc1){ref-type="supplementary-material"}C).

In the 3D system, we also used suspended pellet culture for better cell collection. VCRTc-treated MEFs self-organized into dense suspended pellets and were cultured for 4 weeks. Mesenchymal condensation marker N-cadherin was expressed in early phase (day 7--10) and SOX9 was continuously expressed during chondrogenic induction, and presented in a higher expression level in late period (days 13--20) ([Figure S2](#mmc1){ref-type="supplementary-material"}C). The pellets grew in size over time ([Figure 2](#fig2){ref-type="fig"}C) and expressed Col2 from day 20 ([Figure 2](#fig2){ref-type="fig"}A).Figure 2Chemical-Induced Chondrocytes Form Scaffold-free Cartilage Organoids(A) Representative images of real-time Col2-pd2EGFP observation in 3D ci-chons. Scale bars, 200 μm.(B) The percentage of viable cells during 3D chondrogenic induction, characterized by trypan blue staining. Independent experiments, n = 3.(C) The number of large-size pellets (diameter\>200 μm) per 5 × 10^6^ cells during 3D chondrogenic induction. Independent experiments, n = 3.(D) Flow cytometry analysis of Col2-pd2EGFP^+^ efficiency in MEF and ci-chon pellets.(E) Immunostaining of chondrocyte markers: aggrecan (ACAN), COL2, proteoglyacan 4 (PRG4), SOX9, and collagen type I (COL1) in MEF and ci-chon pellets. Scale bars, 50 μm.(F) Efficiency quantification of ACAN, COL2, PRG4, SOX9, and COL1 immunostaining in MEF and ci-chon pellets. Independent experiments, n = 3.Data are means ± SEM, n ≥ 3. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. See also in [Figure S2](#mmc1){ref-type="supplementary-material"}.

Flow cytometric analysis showed that ∼20% of the cells in the chemical-induced chondrocyte pellets (ci-chon pellets) expressed Col2 ([Figure 2](#fig2){ref-type="fig"}B), much more than those in the monolayer-induced cells ([Figure 1](#fig1){ref-type="fig"}F). Immunostaining revealed that 3D-induced ci-chon pellets showed higher expression levels in aggrecan (ACAN), COL2, proteoglyacan 4 (PRG4), and SOX9 relative to MEF pellets (45.33% ± 2.30% vs 3.72% ± 0.19%; 28.41% ± 1.70% vs 2.27% ± 0.96%; 61.15% ± 4.56% vs 8.67% ± 0.66%; 47.24% ± 7.31% vs 8.56% ± 5.17%) ([Figures 2](#fig2){ref-type="fig"}E and 2F). The expression of fibroblast/fibrocartilage marker COL1 was lower in ci-chon pellets when compared with MEF pellets (51.01% ± 4.62% vs 76.05% ± 6.69%). The proportion of hypertrophic marker COL10 and RUNX2 was also examined in ci-chon and MEF pellets, being 14.14% ± 1.78% vs 16.57% ± 2.68% and 15.34% ± 2.86% vs 3.53% ± 1.56%, respectively ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F).

To characterize ci-chons at mRNA level, we performed single-cell qPCR for 20 osteochondral markers ([Table S4](#mmc3){ref-type="supplementary-material"}). We used MEFs as negative controls, and mouse primary articular chondrocytes (mchons) as positive controls. Subpopulations of ci-chons (subclusters) were identified to express chondrocyte signatures, their proportion of representative chondrocyte markers, *Acan*, *Prg4*, *Col11a2*, and *Col2a1*, being 14.29%, 26.79%, 12.50%, and 8.03%, respectively ([Figures S2](#mmc1){ref-type="supplementary-material"}G and S2H). Altogether, we have grown ci-chons as scaffold-free cartilage organoids with an order of magnitude increase in induction efficiency compared with monolayer culture.

Single-Cell Transcriptomics of the Fibroblast-to-Chondrocyte Reprogramming {#sec2.3}
--------------------------------------------------------------------------

High-throughput single-cell RNA sequencing was used to characterize ∼1,400 cells at different reprogramming stages ([Figure S3](#mmc1){ref-type="supplementary-material"}A): 232 MEFs of day 0; 577 VCRTc-treated MEFs of day 6; 311 3D-induced ci-chons of day 34; and 281 mchons as positive controls. Those mchons were isolated from newborn murine articular cartilages of knee joints based on previously published methods ([@bib40]) ([Figure S3](#mmc1){ref-type="supplementary-material"}B).

In single-cell RNA sequencing, 6.7 × 10^5^ reads and 3,684 genes were detected on average in each cell. We performed Seurat unbiased clustering and visualized cell expression profiles in two dimensions using principal-component analysis plot. Three clusters were well segregated ([Figures 3](#fig3){ref-type="fig"}A and 3B) with a mean of 660 marker genes for each cluster ([Figure 3](#fig3){ref-type="fig"}B; [Table S3](#mmc2){ref-type="supplementary-material"}). Among the four cell types, ci-chons were classified into the same cluster (cluster 3) with primary chondrocytes, which was clearly distinct from clusters of MEFs and 6-day fibroblasts (clusters 1 and 2, [Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}C), indicating similar transcriptional patterns in ci-chons and mchons ([Figure 3](#fig3){ref-type="fig"}B). Nearly 100% of VCRTc-treated fibroblasts of day 6 belonged to cluster 2, which occupied 81.01% of this cluster ([Figure S3](#mmc1){ref-type="supplementary-material"}C). They showed intermediate features between day 0 MEFs and day 34 ci-chons, and thereby were termed chemical-induced intermediate cells (ci-ICs). Gene ontology (GO) analysis ([Figure 3](#fig3){ref-type="fig"}D), showed that cluster 3 was dominated by genes regulating cartilage extracellular matrix (ECM) ([Figure 3](#fig3){ref-type="fig"}C), while cluster 1 (99.8% MEFs, [Figures 3](#fig3){ref-type="fig"}C, 3D, and [S3](#mmc1){ref-type="supplementary-material"}C) was relatively enriched in sterol biosynthesis and lipid metabolic process GO terms. ECM remodeling and metalloendopeptidase activity GO terms were enriched in cluster 2 ([Figure 3](#fig3){ref-type="fig"}D).Figure 3Single-Cell Transcriptomics of the Fibroblast-to-Chondrocyte Reprogramming(A and B) (A) Principal-component analysis (PCA) plot of Seurat unbiased clustering of 232 MEFs, 577 VCRTc-treated MEFs (chemical-induced intermediate cells, ci-ICs); (B) 311 ci-chons, and 281 mouse primary chondrocytes (mchons), marked by cell types and clusters 1, 2, and 3.(C and D) (C) Heatmap of marker genes and (D) top five enriched gene ontology (GO) terms in clusters 1, 2, and 3, classified by Seurat unbiased clustering.(E) Heatmap of representative lineage genes in comparison of MEFs, ci-chons, and mchons.(F) Representative genes identifying phenotype of ci-chons. Data of single-cell RNA sequencing.Data are means ± SEM, n ≥ 3. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. See also in [Figure S3](#mmc1){ref-type="supplementary-material"}.

To better delineate the fibroblast-to-chondrocyte reprogramming, we analyzed representative lineage markers in MEFs, ci-chons, and mchons ([Figure 3](#fig3){ref-type="fig"}E). Chondrocyte markers (*Ucma*, *Col2a1*, *Col11a2*, and *Col9a1*) were expressed in 37.6% of the ci-chons and 99.6% of mchons, whereas 96.6% of MEFs showed high expression levels of fibroblast markers, including *Postn*, *Fsp1*, and *Fbln5* ([Figure 3](#fig3){ref-type="fig"}E). To identify the subtype of obtained chondrocytes, we found that *Prg4*, a biomarker of articular surfaces ([@bib29]), was expressed in ∼52% of ci-chons (p \< 0.001, [Figure 3](#fig3){ref-type="fig"}F), which was also validated by immunostaining ([Figures 2](#fig2){ref-type="fig"}E and 2F). Thus, ci-chons shared a similar but not identical gene expression profile to those of mchons. On the other hand, ci-chons expressed moderate levels of the fibroblast marker *Col1a1*, which was lower than that seen in MEFs, suggesting that fibroblast features had been partially erased during the induction ([Figure 3](#fig3){ref-type="fig"}F).

Intermediate Cellular Programs Resemble Cartilage Development {#sec2.4}
-------------------------------------------------------------

Our screen data suggested that the chemical treatment in stage 1 (day 0--6) was potentially critical for the final chondrocyte yield ([Figures 1](#fig1){ref-type="fig"}E, 1F, [S1](#mmc1){ref-type="supplementary-material"}E, and S1K), during which ci-ICs were produced. To understand the chondrogenic features of ci-ICs, we reconstructed the pseudo-temporal trajectory of 577 ci-ICs and 311 ci-chons. By R package Monocle, ci-ICs were classified into two distinct clusters ([Figure 4](#fig4){ref-type="fig"}A). The cluster in an earlier pseudo-time order was marked by proliferative genes, such as *Mki67* ([Figures 4](#fig4){ref-type="fig"}A and 4C). The later ci-IC clusters showed expression of skeletogenesis molecules, including *Bmp6*, *Tgfb2*, *Wnt4*, and *Ecm1* ([Figure 4](#fig4){ref-type="fig"}C), all involved in cartilage development ([@bib26], [@bib28], [@bib37], [@bib42]). These ci-ICs with cartilage developmental features, were termed chondrogenic intermediate cells (Chondrogenic ICs). Expression of chondrocyte markers *Prg4*, *Mgp*, and *Cilp* were gradually upregulated during induction and reached maximum expression levels in ci-chons ([Figure 4](#fig4){ref-type="fig"}C). Together with our observations on the spontaneous organization of ci-ICs during cartilage organoid induction ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C), the cellular programs of the ci-IC subpopulations resembled the process of cartilage formation during embryonic skeletogenesis, which consists of cell condensation, proliferation, and differentiation/ECM production ([@bib23]). These results were also consistent with our previous clustering analysis ([Figure 3](#fig3){ref-type="fig"}D), demonstrating the enrichment of GO terms for ECM organization in ci-ICs.Figure 4Intermediate Cellular Programs Resemble Cartilage Development(A) Trajectory reconstruction of chondrogenesis induction process reveals subpopulations in ci-ICs: proliferative intermediate cells (Proliferative ICs) and chondrogenic intermediate cells (Chondrogenic ICs).(B) Gene expression heatmap of top 1,000 differentially expressed genes in a pseudo-temporal order.(C) Expression dynamics of representative marker genes in proliferative ICs, chondrogenic ICs, and ci-chons.(D) T-SNE plot visualization of 7 ci-IC clusters.(E) Heatmap and the corresponding representative genes in 7 ci-IC clusters.(F) Enriched GO terms in clusters 1, 3, and 7, marked by GO terms of ECM modeling or osteochondrogenesis.See also in [Figure S3](#mmc1){ref-type="supplementary-material"}.

We further dissected the ci-IC subpopulations using Seurat unbiased clustering, classifying the 577 ci-ICs into 7 clusters, based on a total of 764 differentially expressed markers ([Figures 4](#fig4){ref-type="fig"}D--4F, [S3](#mmc1){ref-type="supplementary-material"}D, and S3E). GO terms of ECM region/protein binding were enriched in 3 clusters ([Figure 4](#fig4){ref-type="fig"}F). Cluster 3 (16.3% of ci-ICs) was identified to govern osteochondrogenesis regulation/protein complex binding, marked by genes of cartilage/skeletal formation: *Col11a1*, *Ecm1*, *Spon1*, and *Mgp* ([@bib15], [@bib28], [@bib36], [@bib46]) ([Figure 4](#fig4){ref-type="fig"}F). Clusters 1 (22.5% of ci-ICs) and 7 (8.0% of ci-ICs) were enriched for ECM interactions and proteolysis signatures, and showed high expression levels of metalloendopeptidase genes for ECM proteolysis and remodeling ([@bib49]) ([Figures 4](#fig4){ref-type="fig"}E and 4F). Collectively, we have uncovered cartilage developmental features in ci-IC subpopulations, where both anabolic and catabolic molecules were stimulated for ECM remodeling, resembling early cartilage development.

Fibroblast Feature Inhibition and Chondrogenesis Activation in Early Reprogramming {#sec2.5}
----------------------------------------------------------------------------------

Having identified the chondrogenic subpopulations in ci-ICs, we further investigated the major regulatory molecules driving fibroblast-to-chondrocyte reprogramming, especially during the initial stage (stage 1).

Different from MEFs, ci-ICs exhibited a reduced F-actin staining, a distinct shape, and decreased cell size ([Figures 5](#fig5){ref-type="fig"}A--5D). We monitored the transcriptome profiles of MEFs and ci-ICs using DESeq2, and identified 2,811 differentially expressed genes (adjusted p \<0.01, fold change \>2). GO terms relevant to developmental protein, embryonic limb morphology and osteogenesis were enriched in ci-ICs ([Figure 5](#fig5){ref-type="fig"}E). Consistently, in a functionally grouped network constructed by CytoScape ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B), terms for cartilage development and chondrocyte differentiation were present in upregulated networks ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Volcano plots confirmed that cartilage developmental markers (*Tgfb2*, *Wnt2*, and *Bmp6*) showed enhanced expression in ci-ICs, and that fibroblast markers (*Mfap4*, *S100a4*/*Fsp1*, and *Fbln5*) were highly expressed in MEFs ([Figure S4](#mmc1){ref-type="supplementary-material"}C).Figure 5Fibroblast Feature Inhibition and Chondrogenesis Activation in Early Reprogramming(A) Representative images of F-actin (phalloidin) staining in MEFs and ci-ICs. Scale bars, 100 μm.(B) Relative cell viability of MEFs and ci-ICs. Independent experiments, n = 3.(C and D) (C) Cell size and (D) nucleus area of MEFs and ci-ICs. Independent experiments, n \> 3.(E) GO analysis of differentially expressed genes in ci-ICs relative to MEFs.(F and G) (F) Upregulated and (G) downregulated KEGG pathways in ci-ICs, relative to MEFs.(H) PCA plot displaying bulk RNA profiles of MEFs treated by individual compounds of VCRTc. Untreated MEFs/ci-ICs served as negative/positive controls.(I and J) Heatmap of representative genes activation/inhibition in involved pathways in MEFs treated by individual compounds.(K) Characterization of individual compounds\' effect on fibroblast-to-chondrocyte conversion, characterized by Col2-pd2EGFP^+^ efficiency. Independent experiments, n = 3.Data are means ± SEM, n ≥ 3.^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. See also in [Figures S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}.

We also performed single-cell qPCR in 112 ci-ICs, detecting 96 genes correlated with osteochondral development, chondrocyte/fibroblast lineage, and stemness/pluripotency ([Table S4](#mmc3){ref-type="supplementary-material"}). Consistently, we found that genes responsible for mesoderm development or chondrogenic progenitor (*Wnt9a*, *Tcf15*, and *Gli1*) ([@bib7]) were expressed in a higher proportion of ci-ICs, whereas fibroblast-associated genes, such as *Fsp1*, *Fbln5*, and *Mfap4*, were expressed in a lower proportion in ci-ICs ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E) relative to MEFs. Bulk qPCR demonstrated that ci-ICs obtained increased expression levels of osteochondral developmental markers on day6 (*Tcf15*, *Foxf1a*, and *Meox1*) ([Figure S4](#mmc1){ref-type="supplementary-material"}F). In immunostaining tests, ci-ICs did not exhibit a proliferative activation (marker KI67) or a feature of pluripotency (OCT4) ([Figure S4](#mmc1){ref-type="supplementary-material"}G).

Analysis of KEGG pathways ([Figures 5](#fig5){ref-type="fig"}F and 5G) indicated some pathways are upregulated in ci-ICs: protein digestion/absorption, ECM interaction, Wnt, phosphatidylinositol 3-kinase (PI3K)-Akt, and Hippo pathway, all highly correlated with chondrocyte differentiation ([@bib6], [@bib14], [@bib27], [@bib30]) ([Figure 5](#fig5){ref-type="fig"}F). Relative to MEFs, cytoskeleton-related pathways were relatively inhibited in ci-ICs ([Figure 5](#fig5){ref-type="fig"}G).

To understand the contribution of the individual compounds on early reprogramming, we used bulk RNA sequencing of MEFs treated with VPA, CHIR-98014, Repsox, TTNPB, and celecoxib, respectively. Untreated MEFs and ci-ICs served as negative/positive controls ([Figure 5](#fig5){ref-type="fig"}H). According to KEGG pathways involved in early reprogramming ([Figures 5](#fig5){ref-type="fig"}F and 5G), we characterized the effect of individual compounds on the representative genes in these pathways ([Figures 5](#fig5){ref-type="fig"}I and 5J). TTNPB was responsible for upregulating ∼35% of Wnt pathway genes and ∼52% of TGF-β/Smad pathway genes (adjusted p \< 0.01, fold change \>2) ([Figure 5](#fig5){ref-type="fig"}I). Celecoxib slightly upregulated TGF-β/Smad pathway (29%) ([Figure 5](#fig5){ref-type="fig"}I). VPA contributed to 60% of PI3K-Akt pathway activation ([Figure 5](#fig5){ref-type="fig"}I). Representative fibroblast-specific genes (*Fsp1*, *Fbln5*, and *Thy1*), Rap1 signaling, and cytoskeleton-associated genes in MEFs were repressed by Repsox ([Figure 5](#fig5){ref-type="fig"}J). Celecoxib also inhibited Rap1 signaling genes (30%) and cytoskeleton-associated genes (34%) ([Figure 5](#fig5){ref-type="fig"}J).

Consistent with single-cell transcription data ([Figure 3](#fig3){ref-type="fig"}D), lipid metabolic genes were significantly suppressed in ci-ICs (adjusted p \< 0.01, fold change \>2) ([Figure S4](#mmc1){ref-type="supplementary-material"}H). VPA, TTNPB, and celecoxib were responsible for suppressing ∼39%, ∼40%, and ∼37%, respectively, of genes under these GO terms (sterol biosynthetic process and lipid metabolic process). However, CHIR-98014 and Repsox did not contribute to fat metabolism inhibition. We knocked down representative fat metabolic genes (*Ptgs1*, *Ldlr*, *Pcsk9*, and *Scd1*), as all of these genes were not completely suppressed in samples treated by individual compounds ([Figure S4](#mmc1){ref-type="supplementary-material"}H). We hypothesized that further inhibition of these genes might promote lineage conversion, and found that effective knockdown of *Ldlr* and *Pcsk9* could significantly increase both Saffranin O^+^ and Col2-pd2EGFP^+^ efficiency when compared with control group ([Figures S4](#mmc1){ref-type="supplementary-material"}H--S4M, p \< 0.001).

The Col2-pd2EGFP reporter system was also used to characterize the requirement of individual compounds\' function, revealing that elimination of TTNPB or celecoxib significantly (p \< 0.05) reduced reprogramming efficiency ([Figure 5](#fig5){ref-type="fig"}K). Thus, the VCRTc cocktail drives fibroblasts into a chondrogenic intermediate state by inhibiting fibroblast features, cytoskeleton, and fat metabolism signaling pathways, and upregulating cartilage developmental genes, through the activation of Wnt and PI3K-Akt pathway.

To exclude the possibility of a minor MEF subpopulation selectively proliferating and differentiating into chondrocytes, we compared cell subpopulations in MEFs and ci-ICs. Based on our Seurat unbiased clustering, ∼59% of MEFs were classified into cluster 2 which also contained ci-ICs ([Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}C). We analyzed representative fate markers in the two MEF subpopulations ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). When compared with MEF-1 (MEFs in cluster 1), MEF-2 (MEFs in custer 2) had diminished expression levels of fibroblast markers. However, both MEF subpopulations were clearly distinguished from ci-ICs, showing higher expression levels of fibroblast markers and lower levels of chondrogenesis markers ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B), indicating that MEF-2 cells are unlikely to have selectively proliferated to form ci-ICs. To avoid the presence of mesenchymal stem cells or cartilage stem cells in MEFs, we analyzed the expression patterns of stem cell markers in MEF-1, MEF-2, and ci-ICs ([Figure S5](#mmc1){ref-type="supplementary-material"}C). None of MEF subpopulation met the criteria of mesenchymal stem cells (CD73^+^/CD90^+^/CD105^+^/CD166^+^) ([@bib9]), nor that of cartilage-derived stem cells (CD73^+^/CD90^+^/CD105^+^/CD146^+^/CD166^+^) ([@bib22]), as stem cell markers were not co-expressed in any single MEF or ci-IC ([Figure S6](#mmc1){ref-type="supplementary-material"}C).

Overall, we demonstrated that (1) ci-ICs obtained chondrogenic progenitor features with higher expression of cartilage developmental genes in early stage; (2) the fibroblast features in ci-ICs were suppressed; and (3) ci-ICs do not exhibit pluripotent/stem cell features.

*In Vivo* Cartilage Regeneration by Chemical-Induced Chondrocytes {#sec2.6}
-----------------------------------------------------------------

Having demonstrated the similarities between articular chondrocytes and ci-chons, we wished to test the *in situ* regenerative function of ci-chons. TdTomato-tagged (for *in vivo* tracing) ci-chon pellets (2 × 10^5^ cells) were implanted into a full-thickness cartilage defect model validated by other groups ([@bib10], [@bib47]). Histological images demonstrated regenerated Safranin O^+^ cartilage tissues in the ci-chon group (implanted with ci-chons) ([Figure 6](#fig6){ref-type="fig"}A), as well as fibrous tissues in the MEF group (implanted with MEF pellets) and the blank group (without cell implantation). Quantitative ICRS-II scoring demonstrated that the implantation of ci-chons led to improved cartilage matrix formation and tissue morphology among the other groups ([Figures 6](#fig6){ref-type="fig"}B and [S6](#mmc1){ref-type="supplementary-material"}A). The ci-chon group also exhibited promoted healing with reduced remaining defect area when compared with MEF group ([Figure 6](#fig6){ref-type="fig"}F). The expression of COL1 was significantly decreased in the cartilage layer of the ci-chons group, indicating that the implantation of ci-chons reduced the articular surface fibrosis ([Figures S6](#mmc1){ref-type="supplementary-material"}C and S6D).Figure 6*In Vivo* Cartilage Regeneration by Chemical-Induced Chondrocytes(A) Representative images of repaired cartilages in full-thickness cartilage defect model, stained by Safranin O-fast green. Blank group: defect without cell transplantation. Scale bars, 100 μm.(B) Representative ICRS-II parameter quantification of the regenerative cartilages in blank, MEF, and ci-chon group (blinded scores of 4 individuals, n = 5 for each group).(C) Co-labelling of tdTomato tracing tag and COL2 in injured sites. Scale bars, 50 μm.(D) General Safranin O-fast green image of the sample in [Figure 6](#fig6){ref-type="fig"}C.(E) Quantification of chondrocytes derived from host cells versus ci-chons in injured sites (n = 5).(F) The diameter of remaining unfilled defects (n = 5), calculated based on Safranin O-fast green images ([Figure S6](#mmc1){ref-type="supplementary-material"}A).(G) Effective indentation modulus (Eind), of healthy cartilage (sham group), and repaired cartilages in blank, MEF, and ci-chons groups (n ≥ 3 for each group and 5 measured locations for each sample).(H) Typical indentation force-versus-depth curves of repaired cartilage defects.Data are means ± SEM, n ≥ 5. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. See also in [Figure S6](#mmc1){ref-type="supplementary-material"}.

To eliminate concerns of the spontaneous recovery in the murine model, we also evaluated the contribution of implanted ci-chon pellets to COL2^+^ cartilage regeneration by tdTomoto tracing. tdTomato was detected in the newly formed tissues by immunofluorescence, with co-localization of COL2 ([Figure 6](#fig6){ref-type="fig"}C). More than 60% of the regenerative chondrocytes were identified as tdTomato/COL2 double-positive cells, confirming that ci-chons contributed to most of the newly regenerative cartilage ([Figures 6](#fig6){ref-type="fig"}C--6E).

As mechanical properties are important indicators of cartilage function, we used atomic force microscopy (AFM)-based nanoindentation to quantify the effective indentation modulus (Eind), of recovered tissues in the middle of the femoral trochlear groove ([Figures 6](#fig6){ref-type="fig"}G and 6H). A stiffness loss was observed in defective cartilages, as reported previously ([@bib12]). The cartilages in the sham group were regarded as healthy positive controls. The Eind of the blank group was reduced to 25% of that in the sham group (34.50 ± 8.38 vs 124.72 ± 13.7 kPa), even given the potential to spontaneously recovery 6 weeks after surgery ([Figures 6](#fig6){ref-type="fig"}G and 6H). MEF implantation provided no recovery of mechanical function, the Eind remaining at ∼13% of the level of heathy cartilage (16.76 ± 6.59 kPa). In contrast, 63.4% of the modulus loss was rescued by ci-chon implantation (79.04 ± 14.83 vs 124.72 ± 13.7 kPa in sham group). Thus, we demonstrated that ci-chon implantation contributed substantially to the histological and mechanical recovery of articular cartilage defects, and also reduced fibrosis at articular surfaces.

Discussion {#sec3}
==========

The need for a reliable supply of functional chondrocytes has motivated us to develop a chemical-based approach for the induction of chondrocytes. In this study, we used a 3D induction system and the VCRTc cocktail to directly reprogram mouse fibroblasts into articular chondrocytes, which are capable of enhancing mechanical and histological repair at knee joint surfaces. Our single-cell transcriptome analysis of the fibroblast-to-chondrocyte conversion has also uncovered intermediate cellular states resembling chondrogenic progenitors, primed for a cartilage developmental fate.

Small molecule-based cell reprogramming has significant advantages over gene-induced reprogramming as it has been reported to be non-tumourigenic and non-immunogenic ([@bib52]). Furthermore, we developed the VCRTc cocktail through the combinatorial screening of a library of Food and Drug Administration-approved drugs and common bioactive inhibitors. The cocktail includes celecoxib and TTNPB, which were potentially essential for our reprogramming ([Figure 5](#fig5){ref-type="fig"}K). Regarding the underlying mechanism(s), TTNPB is a retinoic acid receptor (RAR) agonist that has been used for inducing mesoderm from pluripotent cells ([@bib1]). In other reports, RARβ2 was required for vertebrate somitogenesis ([@bib21]), which was an early process of skeletogenesis, supporting that TTNPB was helpful to trigger cartilage development. Celecoxib is a COX-2 selective non-steroidal anti-inflammatory drug that has been used in osteoarthritis treatment for decades ([@bib33]) and also applied as a fibrosis inhibitor ([@bib24]). In our data, celecoxib significantly inhibited cytoskeleton-associated genes and lipid metabolic genes, consistent with published results that it could modulate actin organization ([@bib2]) and decrease fat deposition ([@bib32]). Details of how the two compounds helped drive the fibroblast-to-chondrocyte reprogramming remain to be investigated, but our findings suggest that they have potential in future cartilage regenerative therapy. In addition, we found that effective repression of *Ldlr* and *Pcks9* could increase reprogramming efficiency as both molecules played important roles in lipid metabolism. Low-density lipoprotein receptor (LDLR) is a transport protein that facilitates cholesterol entry into cells ([@bib4]) and can interact with proprotein convertase subtilisin/kexin 9 (PCSK9) ([@bib43]). LDLR is expressed in vascular smooth muscle cells similarly to osteochondro-progenitors within atherosclerotic plaques ([@bib31]), and may participate in osteogenesis homeostasis ([@bib13]). The underlying mechanisms of LDLR and PCSK9 mediating cartilage formation need further investigation, but our data suggest that lipid metabolism can be a potential target for chemical reprogramming facilitation.

Chemical reprogramming also offers an *in vitro* model for investigating cell fate decisions. By analyzing the profiles of ∼1,400 single cells at multiple time points, we have uncovered an embryonic skeletogenesis-like fate in cells at an intermediate stage, termed "ci-ICs" ([Figure 4](#fig4){ref-type="fig"}). In an effort to identify the cell subpopulation that gives rise to the chondrogenic fate, we characterized a MEF subpopulation (MEF-2, [Figure S5](#mmc1){ref-type="supplementary-material"}A) with specific similarities to ci-ICs when compared with other MEFs. However, all MEF subpopulations were distinguished from ci-ICs in that they showed higher expression of genes associated with fibroblast features and lower expression levels of chondrogenesis markers ([Figures S5](#mmc1){ref-type="supplementary-material"}B and S5C), suggesting that the MEF-2 subpopulation is not likely to selectively form ci-ICs. Neither MEF subpopulations nor ci-ICs possessed the characteristics of mesenchymal stem cells or cartilage stem cells ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Altogether, our findings suggest that the VCRTc chemical cocktail plays a significant role in cell phenotype and plasticity remodeling, which drives MEFs into a chondrogenic fate through the inhibition of fibroblast features and stimulation of chondrogenesis programs. Our chemical-based approach directly reprogramming MEFs into chondrocytes bypassing a stem cell stage ([Figures 5](#fig5){ref-type="fig"} and [S5](#mmc1){ref-type="supplementary-material"}) poses a lower risk for tumor development and shortens induction times.

Cartilage is a load-bearing tissue, thus mechanical properties were regarded as important indicators of cartilage function. Using AFM nanoindentation, we have demonstrated that the implantation of ci-chons rescued 63.4% of the mechanical property loss and contributed over 60% of the newly regenerative cartilage ([Figure 6](#fig6){ref-type="fig"}). We suggest that these results are attributed to the 3D self-organized organoids maintaining a more chondrocyte-like phenotype compared with cells derived from 2D dish cultures ([Figure 2](#fig2){ref-type="fig"}). Formation of fibrous tissue is the principal cause of joint pain and functional loss ([@bib39]). Indeed, MEF implantation did not improve, and in some cases even worsened the recovery of, joint mechanical properties ([Figures 6](#fig6){ref-type="fig"}B, 6G, and 6H). Our insights into the reprogramming pathway illustrate that strategies, such as inhibiting fibroblast features and remodeling ECM, might be used to reprogram fibrous tissues into functional cartilage *in situ*, thereby rescuing mechanical property loss and promoting chondrocyte redistribution.

In summary, using a cocktail composed of Food and Drug Administration-approved small molecules, we have developed a chemical method to derive functional articular chondrocytes from fibroblasts, which promote regeneration of articular cartilage defects. Through the analysis of single-cell fate dynamics during the chemical reprogramming, we identify the transition of MEFs into an intermediate cell population resembling chondrogenic progenitors. With further optimization, we believe our method will provide a strategy for understanding and manipulating cell fate conversion for cartilage regeneration.

Experimental Procedures {#sec4}
=======================

Chemical Induction (Stage 1) {#sec4.1}
----------------------------

Expanded MEFs that had been cultured in H-DMEM for 48 h (confluency 90%) were then transferred into a chemical conditional medium and maintained for 6 days. The chemical conditional medium was composed of KnockOut Serum Replacer (KSR) medium (Life Technologies), 15% knockout serum replacement, 1% nonessential amino acid (Invitrogen), 1% GlutaMax (Gibico), 1% sodium pyruvate (Gibico), 0.1 mM β-mercaptoethanol (Millipore), and 1,000 U/mL leukemia inhibitory factor (PeproTech). In primary screening, chemical cocktail VCR (valproic acid, 500 μM, Sigma; CHIR-98014, 3 μM Selleck; Repsox (E616542), 1 μM, Selleck) were added in KSR medium. In the optimized induction approach, VCRTc (VCR plus TTNPB, 3 μM, Selleck; celecoxib, 5 μM, Selleck) were added in KSR medium. Cells were cultured at 37°C under 5% O~2~ (hypoxia) and 5% CO~2~ in an O~2~/CO~2~ incubator (MCO-5M, Sanyo). Medium was changed every 3 days.

Chondrogenic Differentiation (Stage 2) {#sec4.2}
--------------------------------------

To start stage 2 for monolayer-induced cells, KSR medium was changed to chondrogenic differentiation medium (H-DMEM supplemented with 10^−7^ M dexamethasone \[Sigma\], 50 mg/mL ascorbic acid \[Sigma\], 1 mM sodium pyruvate \[Gibico\], 1% ITS + premix \[Gibico\], and 10 ng/mL TGF-β3 \[PeproTech\]). For micromass culture, 2 × 10^5^ ci-chons were collected by 0.05% trypsin digestion, suspended in 10 μL medium, and seeded on a Petri dish to form a high-density cell aggregation. After a 3-h-incubation, chondrogenic medium was added. For pellet suspension culture, 2 × 10^6^ cells were collected by 0.05% trypsin digestion, mixed with chondrogenic differentiation medium, and seeded into a Corning Ultra-Low Attachment 6-well plate. After cells formed aggregations spontaneously, medium could be changed every 3 days. The induction duration for monolayer, micromass, and pellet culture were 14, 14, and 28 days, respectively.

Drug Screening for Chondrogenesis-Inducing Cocktails {#sec4.3}
----------------------------------------------------

In brief, in primary screening, we selected 48 small molecules ([Table S1](#mmc1){ref-type="supplementary-material"}) that were known to facilitate reprogramming or regulate chondrogenesis from a chemical library (Selleck). Each compound was applied at either stage 1 or 2, respectively (96 conditions, [Figure 1](#fig1){ref-type="fig"}A). We identified 5 compounds ([Table S2](#mmc1){ref-type="supplementary-material"}) as candidates in combinatory screening as they potentially improved reprogramming efficiency. In the combinatory screening, we then tested 30 different combinations of these 5 candidates together with the VCR cocktail. We conducted Safranin O-fast green staining at the end of induction.

Single-Cell RNA Sequencing {#sec4.4}
--------------------------

Single cells were loaded on a high-throughput Fluidigm C1 IFC. Cell number in each microfluidic chamber was checked under a microscope. Then cell lysis, reverse transcription, and cDNA pre-amplification were performed on the chip according to Fluidigm\'s standard protocol. Illumina libraries were prepared by Illumina Nextera XT DNA Sample Preparation Kit. Libraries were pooled and sequenced at 150-bp paired-end on one lane of Illumina HiSeq X Ten. After obtaining the digital gene expression data matrix, we used Seurat for dimension reduction, clustering, and differential gene expression analysis, following the publicly available guided tutorials (<http://www.satijalab.org/seurat>) ([@bib41]). R Bioconductor package Monocle ([@bib44]) was used in cell clustering and pseudo-time analysis.

Statistical Analysis {#sec4.5}
--------------------

Statistical analysis was performed using GraphPad Prism 5 software. We used unpaired t test for comparisons of the two groups, with Mann-Whitney test (nonparametric) for data not fitting Gaussian distribution. To analyze three or more groups, we used a one-way ANOVA test to identify overall difference, and Tukey test to compare all pairs of groups, or Dunnett's test to compare all groups versus the control group. For nonparametric tests of three or more groups, Kruskal-Wallis test plus Dunn's test was applied. Data are shown as mean ± SEM. All data shown were repeated at least three times. No samples were measured repeatedly. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.
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